TY - JOUR
T1 - Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium
AU - Shete, Sanjay
AU - Lau, Ching C
AU - Houlston, Richard S
AU - Claus, Elizabeth B
AU - Barnholtz-Sloan, Jill
AU - Lai, Rose
AU - Il'yasova, Dora
AU - Schildkraut, Joellen
AU - Sadetzki, Siegal
AU - Johansen, Christoffer
AU - Bernstein, Jonine L
AU - Olson, Sara H
AU - Jenkins, Robert B
AU - Yang, Ping
AU - Vick, Nicholas A
AU - Wrensch, Margaret
AU - Davis, Faith G
AU - McCarthy, Bridget J
AU - Leung, Eastwood Hon-chiu
AU - Davis, Caleb
AU - Cheng, Rita
AU - Hosking, Fay J
AU - Armstrong, Georgina N
AU - Liu, Yanhong
AU - Yu, Robert K
AU - Henriksson, Roger
AU - Melin, Beatrice S
AU - Bondy, Melissa L
AU - Gliogene Consortium
AU - Broholm, Helle
PY - 2011
Y1 - 2011
N2 - Gliomas, which generally have a poor prognosis, are the most common primary malignant brain tumors in adults. Recent genome-wide association studies have shown that inherited susceptibility plays a role in the development of glioma. Although first-degree relatives of patients exhibit a two-fold increased risk of glioma, the search for susceptibility loci in familial forms of the disease has been challenging because the disease is relatively rare, fatal, and heterogeneous, making it difficult to collect sufficient biosamples from families for statistical power. To address this challenge, the Genetic Epidemiology of Glioma International Consortium (Gliogene) was formed to collect DNA samples from families with two or more cases of histologically confirmed glioma. In this study, we present results obtained from 46 U.S. families in which multipoint linkage analyses were undertaken using nonparametric (model-free) methods. After removal of high linkage disequilibrium single-nucleotide polymorphism, we obtained a maximum nonparametric linkage score (NPL) of 3.39 (P = 0.0005) at 17q12-21.32 and the Z-score of 4.20 (P = 0.000007). To replicate our findings, we genotyped 29 independent U.S. families and obtained a maximum NPL score of 1.26 (P = 0.008) and the Z-score of 1.47 (P = 0.035). Accounting for the genetic heterogeneity using the ordered subset analysis approach, the combined analyses of 75 families resulted in a maximum NPL score of 3.81 (P = 0.00001). The genomic regions we have implicated in this study may offer novel insights into glioma susceptibility, focusing future work to identify genes that cause familial glioma.
AB - Gliomas, which generally have a poor prognosis, are the most common primary malignant brain tumors in adults. Recent genome-wide association studies have shown that inherited susceptibility plays a role in the development of glioma. Although first-degree relatives of patients exhibit a two-fold increased risk of glioma, the search for susceptibility loci in familial forms of the disease has been challenging because the disease is relatively rare, fatal, and heterogeneous, making it difficult to collect sufficient biosamples from families for statistical power. To address this challenge, the Genetic Epidemiology of Glioma International Consortium (Gliogene) was formed to collect DNA samples from families with two or more cases of histologically confirmed glioma. In this study, we present results obtained from 46 U.S. families in which multipoint linkage analyses were undertaken using nonparametric (model-free) methods. After removal of high linkage disequilibrium single-nucleotide polymorphism, we obtained a maximum nonparametric linkage score (NPL) of 3.39 (P = 0.0005) at 17q12-21.32 and the Z-score of 4.20 (P = 0.000007). To replicate our findings, we genotyped 29 independent U.S. families and obtained a maximum NPL score of 1.26 (P = 0.008) and the Z-score of 1.47 (P = 0.035). Accounting for the genetic heterogeneity using the ordered subset analysis approach, the combined analyses of 75 families resulted in a maximum NPL score of 3.81 (P = 0.00001). The genomic regions we have implicated in this study may offer novel insights into glioma susceptibility, focusing future work to identify genes that cause familial glioma.
U2 - 10.1158/0008-5472.CAN-11-0013
DO - 10.1158/0008-5472.CAN-11-0013
M3 - Journal article
C2 - 22037877
SN - 0008-5472
VL - 71
SP - 7568
EP - 7575
JO - Cancer Research
JF - Cancer Research
IS - 24
ER -